IIN Stock Overview
IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$24.23|
|52 Week High||US$26.08|
|52 Week Low||US$12.47|
|1 Month Change||0.96%|
|3 Month Change||48.65%|
|1 Year Change||-4.68%|
|3 Year Change||-2.85%|
|5 Year Change||206.71%|
|Change since IPO||337.23%|
Recent News & Updates
IntriCon's (NASDAQ:IIN) Returns Have Hit A Wall
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...
|IIN||US Medical Equipment||US Market|
Return vs Industry: IIN exceeded the US Medical Equipment industry which returned -16.4% over the past year.
Return vs Market: IIN exceeded the US Market which returned -12.7% over the past year.
|IIN Average Weekly Movement||10.8%|
|Medical Equipment Industry Average Movement||10.5%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.0%|
Stable Share Price: IIN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: IIN's weekly volatility (11%) has been stable over the past year.
About the Company
IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. It offers micro-miniature products, microelectronics, micro-mechanical assemblies, high-precision injection-molded plastic components, and assemblies and software solutions for medical devices, hearing healthcare, and professional audio communication devices markets. The company also provides micro coils for surgical navigation clinical applications, such as interventional pulmonology and electrophysiology; joint engineering and manufacturing services for complex medical devices, including catheters covering a range of applications for cardiology, peripheral vascular, neurology, radiology, and pulmonology; bubble sensors and flow restrictors that monitor and control the flow of fluid in an intravenous infusion system; and safety needle products for original equipment manufacturing customers.
IntriCon Fundamentals Summary
|IIN fundamental statistics|
Is IIN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IIN income statement (TTM)|
|Cost of Revenue||US$94.45m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.16|
|Net Profit Margin||-1.17%|
How did IIN perform over the long term?See historical performance and comparison
Is IntriCon undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IIN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IIN's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: IIN is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: IIN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IIN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IIN's PB Ratio (2.4x) is in line with the US Medical Equipment industry average.
How is IntriCon forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IIN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: IIN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: IIN's is expected to become profitable in the next 3 years.
Revenue vs Market: IIN's revenue (14.1% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: IIN's revenue (14.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IIN's Return on Equity is forecast to be high in 3 years time
How has IntriCon performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IIN is currently unprofitable.
Growing Profit Margin: IIN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IIN is unprofitable, and losses have increased over the past 5 years at a rate of 25.5% per year.
Accelerating Growth: Unable to compare IIN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IIN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.5%).
Return on Equity
High ROE: IIN has a negative Return on Equity (-1.42%), as it is currently unprofitable.
How is IntriCon's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: IIN's short term assets ($76.6M) exceed its short term liabilities ($23.9M).
Long Term Liabilities: IIN's short term assets ($76.6M) exceed its long term liabilities ($8.8M).
Debt to Equity History and Analysis
Debt Level: IIN is debt free.
Reducing Debt: IIN has no debt compared to 5 years ago when its debt to equity ratio was 65.7%.
Debt Coverage: IIN has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: IIN has no debt, therefore coverage of interest payments is not a concern.
What is IntriCon current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IIN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IIN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IIN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IIN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IIN has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
J. Longval (44 yo)
Mr. J. Scott Longval has been Chief Executive Officer, President and Director of IntriCon Corporation since October 1, 2020. He served as an Executive Vice President at IntriCon Corporation until September...
CEO Compensation Analysis
Compensation vs Market: J.'s total compensation ($USD1.30M) is about average for companies of similar size in the US market ($USD1.68M).
Compensation vs Earnings: J.'s compensation has increased whilst the company is unprofitable.
Experienced Management: IIN's management team is considered experienced (2.1 years average tenure).
Experienced Board: IIN's board of directors are considered experienced (4.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.5%.
IntriCon Corporation's employee growth, exchange listings and data sources
- Name: IntriCon Corporation
- Ticker: IIN
- Exchange: NasdaqGM
- Founded: 1930
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$225.395m
- Shares outstanding: 9.30m
- Website: https://www.intricon.com
Number of Employees
- IntriCon Corporation
- 1260 Red Fox Road
- Arden Hills
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/21 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.